...
首页> 外文期刊>Cellular immunology >Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro.
【24h】

Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro.

机译:载有凋亡性肿瘤细胞的自体树突细胞在体外诱导针对乳腺癌的T细胞介导的免疫反应。

获取原文
获取原文并翻译 | 示例
           

摘要

Dendritic cell (DCs) based immunotherapy has received increased interest in the treatment of specific malignancies including breast cancer. In this in vitro study, T cell responses, which are induced by monocyte-derived DCs pulsed with apoptotic breast tumor cells (ApTC), were analyzed in terms of proliferation, specific cytotoxicity, and cytokine release. Nylon wool-enriched T lymphocytes from five patients with breast cancer stimulated with monocyte-derived DCs pulsed with apoptotic tumor cells in vitro and their proliferation response were analyzed by [(3)H] thymidine uptake and specific cytotoxic activity of tumor antigen-primed T cells after three rounds of weekly stimulation by flow cytometry. Interferon-gamma (IFN-gamma) and interleukin-4 (IL-4) cytokine release assay was carried out 24h after the last stimulation. The supernatant from primed T cells was collected and analyzed using commercially available ELISA kits. T cell proliferation assays revealed that DCs pulsed with apoptotic tumor cell could stimulate an autologous T cell proliferation response with stimulation indices of 5-21. The T cell-mediated cytotoxicity assay demonstrated that tumor antigen-primed T cells could kill significantly more autologous tumor cells than normal cells (P<0.05). These cells had variable amounts of cytotoxic activity against K562 cells. Primed T cells released both IFN-gamma and IL-4 in response to re-stimulation by antigen-pulsed DCs, but were dominated by IFN-gamma production in two out of five patients and IL-4 production in three out of five patients. In conclusion, our results suggested that DCs pulsed with apoptotic breast tumor cells could elicit effective specific antitumor T cell responses in vitro. Therefore, vaccination with DCs pulsed with apoptotic tumor cells may be considered as a novel strategy for immunotherapy of patients with breast cancer refractory to standard modalities.
机译:基于树突状细胞(DC)的免疫疗法对包括乳腺癌在内的特定恶性肿瘤的治疗越来越引起人们的兴趣。在这项体外研究中,从增殖,特异性细胞毒性和细胞因子释放方面分析了由单核细胞衍生的DCs刺激的凋亡性乳腺肿瘤细胞(ApTC)诱导的T细胞反应。凋亡的肿瘤细胞对单核细胞衍生的DC刺激的5例乳腺癌患者的尼龙羊毛富集的T淋巴细胞进行体外培养,并通过[(3H)H]胸腺嘧啶核苷的摄取和肿瘤抗原引发的T的特异性细胞毒活性分析了它们的增殖反应流式细胞仪每周刺激三轮后的细胞。最后一次刺激后24小时进行干扰素-γ(IFN-γ)和白介素4(IL-4)细胞因子释放测定。收集来自初免T细胞的上清液,并使用市售ELISA试剂盒进行分析。 T细胞增殖试验表明,用凋亡肿瘤细胞脉冲的DC可以刺激自体T细胞增殖反应,刺激指数为5-21。 T细胞介导的细胞毒性试验表明,肿瘤抗原引发的T细胞比正常细胞可杀死更多的自体肿瘤细胞(P <0.05)。这些细胞对K562细胞具有不同程度的细胞毒活性。引发的T细胞响应抗原脉冲DC的再刺激而释放IFN-γ和IL-4,但在五分之二的患者中IFN-γ产生占主导,五分之三的IL-4产生占主导地位。总之,我们的结果表明,用凋亡的乳腺肿瘤细胞脉冲的DC可以在体外引发有效的特异性抗肿瘤T细胞反应。因此,用凋亡性肿瘤细胞脉冲的DC接种疫苗可被认为是对标准方式难治的乳腺癌患者进行免疫治疗的新策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号